Reference | 1: de Welzen L, Eldholm V, Maharaj K, Manson AL, Earl AM, Pym AS. Whole
transcriptome and genomic analysis of extensively drug-resistant Mycobacterium
tuberculosis clinical isolates identifies downregulation of ethA as a mechanism
of ethionamide resistance. Antimicrob Agents Chemother. 2017 Oct 9. pii:
AAC.01461-17. doi: 10.1128/AAC.01461-17. [Epub ahead of print] PubMed PMID:
28993337.
<br>
2: Khan AM, Shawon J, Halim MA. Multiple receptor conformers based molecular
docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP
reductase (InhA). J Mol Graph Model. 2017 Sep 14;77:386-398. doi:
10.1016/j.jmgm.2017.09.010. [Epub ahead of print] PubMed PMID: 28957755.
<br>
3: Debnath SK, Saisivam S, Omri A. PLGA Ethionamide Nanoparticles for Pulmonary
Delivery: Development and in vivo evaluation of dry powder inhaler. J Pharm
Biomed Anal. 2017 Oct 25;145:854-859. doi: 10.1016/j.jpba.2017.07.051. Epub 2017
Aug 9. PubMed PMID: 28826144.
<br>
4: Zhang HN, Xu ZW, Jiang HW, Wu FL, He X, Liu Y, Guo SJ, Li Y, Bi LJ, Deng JY,
Zhang XE, Tao SC. Cyclic di-GMP regulates Mycobacterium tuberculosis resistance
to ethionamide. Sci Rep. 2017 Jul 19;7(1):5860. doi: 10.1038/s41598-017-06289-7.
PubMed PMID: 28725053; PubMed Central PMCID: PMC5517500.
<br>
5: Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G,
Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP,
Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, Gref R. Combination
therapy for tuberculosis treatment: pulmonary administration of ethionamide and
booster co-loaded nanoparticles. Sci Rep. 2017 Jul 14;7(1):5390. doi:
10.1038/s41598-017-05453-3. PubMed PMID: 28710351; PubMed Central PMCID:
PMC5511234.
<br>
6: Qamar S, Farooqi JQ, Jabeen K, Hasan R. Phenotypic low-level isoniazid
resistance as a marker to predict ethionamide resistance in Mycobacterium
tuberculosis. Int J Mycobacteriol. 2017 Apr-Jun;6(2):167-170. doi:
10.4103/ijmy.ijmy_34_17. PubMed PMID: 28559519.
<br>
7: Wankar J, Salzano G, Pancani E, Benkovics G, Malanga M, Manoli F, Gref R,
Fenyvesi E, Manet I. Efficient loading of ethionamide in cyclodextrin-based
carriers offers enhanced solubility and inhibition of drug crystallization. Int J
Pharm. 2017 Oct 15;531(2):568-576. doi: 10.1016/j.ijpharm.2017.05.041. Epub 2017
May 22. PubMed PMID: 28546070.
<br>
8: Ang MLT, Zainul Rahim SZ, de Sessions PF, Lin W, Koh V, Pethe K, Hibberd ML,
Alonso S. EthA/R-Independent Killing of Mycobacterium tuberculosis by
Ethionamide. Front Microbiol. 2017 Apr 25;8:710. doi: 10.3389/fmicb.2017.00710.
eCollection 2017. PubMed PMID: 28487681; PubMed Central PMCID: PMC5403819.
<br>
9: Nikiforov PO, Blaszczyk M, Surade S, Boshoff HI, Sajid A, Delorme V, Deboosere
N, Brodin P, Baulard AR, Barry CE 3rd, Blundell TL, Abell C. Fragment-Sized EthR
Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell
Mycobacterium tuberculosis Assays. ACS Chem Biol. 2017 May 19;12(5):1390-1396.
doi: 10.1021/acschembio.7b00091. Epub 2017 Apr 5. PubMed PMID: 28314097; PubMed
Central PMCID: PMC5474694.
<br>
10: Vale N, Correia A, Silva S, Figueiredo P, Mäkilä E, Salonen J, Hirvonen J,
Pedrosa J, Santos HA, Fraga A. Preparation and biological evaluation of
ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Bioorg Med Chem Lett. 2017 Feb 1;27(3):403-405. doi: 10.1016/j.bmcl.2016.12.060.
Epub 2016 Dec 26. PubMed PMID: 28057421.
|